Cargando…
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
Intravenous efgartigimod alfa (also known as efgartigimod alfa-fcab in the USA; Vyvgart(®)) is the first neonatal Fc receptor antagonist approved in several countries worldwide, including the USA and EU for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine rec...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212825/ https://www.ncbi.nlm.nih.gov/pubmed/37000339 http://dx.doi.org/10.1007/s40263-023-01000-z |